December 9, 2022 02:03 PM EST

WIB22: Amber Salzman had few options when her son was diagnosed with a rare genetic disease. So she created a better one

This profile is part of Endpoints News’ 2022 special report about Women in Biopharma R&D. You can read the full report

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

WIB22: Am­ber Salz­man had few op­tions when her son was di­ag­nosed with a rare ge­net­ic dis­ease. So she cre­at­ed a bet­ter one